Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients

Drotrecogin alfa (activated) significantly reduced severe sepsis (SevSep) mortality at 28 days [1]. According to the French budget environment, it is mandatory to evaluate its cost effectiveness ratio on a pragmatic basis.